Tag: clinical
Inventiva announces the resumption of screening in the Phase III clinical study, NATiV3, evaluating lanifibranor in NASH – 03/07/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: After a potential serious effect on a patient, Inventiva must pause its clinical trials
(BFM Bourse) – The stock price of the Burgundy biotechnology firm falls after bad news in the context of a clinical study concerning lanifibranor, its most advanced drug candidate against…
Inventiva publishes its preliminary financial information for the 2023 fiscal year¹ and provides an update on its NATiV3 clinical study – 02/15/2024 at 10:35 p.m.
Daix (France), Long Island City (New York, United States), February 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Biosenic raises 500,000 euros to finance an American clinical study
(AOF) – Biosenic announces that it has raised 500,000 euros in gross proceeds through a private placement of 12 million new shares at an issue price of 0.041 euros per…
Dassault Systèmes: The number of clinical trials slows down, sales of Dassault Systèmes software are slipping
(BFM Bourse) – The publisher of computer-aided design and manufacturing software delivered both results below expectations in the fourth quarter as well as disappointing forecasts. The poor performance of licenses…
Valbiotis: commercial and clinical roadmap for 2024
By Olivier Cheilan Published on 01/16/2024 at 6:05 p.m. Photo credit © Valbiotis (Boursier.com) — Valbiotis clarified its…
Transgene and NEC Corporation continue clinical development of TG4050
By Olivier Cheilan Published on 01/08/2024 at 5:58 p.m. (Boursier.com) — Transgene and NEC Corporation announced the signing…
MedinCell – Partner Teva announces the end of patient recruitment in the phase 3 clinical study of mdc-TJK, long-acting injectable treatment of olanzapine – 01/09/2024 at 7:20 p.m.
Teva Pharmaceuticals Industries Ltd., announced at the JP Morgan Healthcare Conference that it has successfully completed recruitment in Europe and the United States of the planned 640 participants in the…
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical study and provides an update on its clinical development program – 12/20/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), December 20, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Merck and co inc: Start of phase III clinical trial with Moderna
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
OSE Immunotherapeutics and the Nantes University Hospital Center present a positive interim analysis of the Phase 1/2 FIRsT clinical trial evaluating FR104/VEL-101 immunotherapy in kidney transplantation – 11/12/2023 at 07:30
At the annual congress of the Société Francophone de Transplantation Supported by the European Society of Organ Transplantation (ESOT) Nantes, France – December 11, 2023, 7:30 a.m. – OSE Immunotherapeutics…
Merck falls after clinical failure of its multiple sclerosis treatment
Published on 06/12/2023 at 10:32 a.m. December 6 (Reuters) – Merck fell on the stock market on Wednesday morning after the announcement of…